Pfizer Halts Studies of DMD Candidate Domagrozumab after Phase II Failure

Pfizer said it will halt two clinical studies of its mid-stage Duchenne muscular dystrophy (DMD) candidate domagrozumab (PF-06252616) following its failure in a Phase II trial, while insisting that it will continue research in DMD and rare neuromuscular diseases.The pharma giant acknowledged that domagrozumab did not meet its primary efficacy endpoint in the Phase II B5161002 trial ( NCT02310763 ), namely demonstrating a difference in the mean change from baseline in 4 Stair Climb (in seconds) f